Second, compared to eGFRcr alone, cystatin C testing (eGFRcys or eGFRcr‐cys) improves detection of high‐risk CKD around the threshold for CKD diagnosis, identifying older individuals who are more likely to benefit from early intervention for cardiovascular disease, kidney failure, and premature death. This evidence concerns the gene CST3 and cardiovascular disorder.